171 related articles for article (PubMed ID: 34298646)
21. Identification of Core Genes and Potential Drugs for Castration-Resistant Prostate Cancer Based on Bioinformatics Analysis.
Liang X; Hu K; Li D; Wang Y; Liu M; Wang X; Zhu W; Wang X; Yang Z; Lu J
DNA Cell Biol; 2020 May; 39(5):836-847. PubMed ID: 32101033
[TBL] [Abstract][Full Text] [Related]
22. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
23. Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer.
Ojo D; Lin X; Wong N; Gu Y; Tang D
Cancers (Basel); 2015 Nov; 7(4):2290-308. PubMed ID: 26593949
[TBL] [Abstract][Full Text] [Related]
24. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.
Shiota M; Yokomizo A; Naito S
Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046
[TBL] [Abstract][Full Text] [Related]
25. Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer.
Hoare D; Skinner TA; Black A; Robert Siemens D
Can Urol Assoc J; 2015; 9(3-4):122-7. PubMed ID: 26085869
[TBL] [Abstract][Full Text] [Related]
26. The role of actinin-4 (ACTN4) in exosomes as a potential novel therapeutic target in castration-resistant prostate cancer.
Ishizuya Y; Uemura M; Narumi R; Tomiyama E; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Imamura R; Adachi J; Tomonaga T; Nonomura N
Biochem Biophys Res Commun; 2020 Mar; 523(3):588-594. PubMed ID: 31941606
[TBL] [Abstract][Full Text] [Related]
27. The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients.
Sasaki T; Sugimura Y
J Clin Med; 2018 Dec; 7(12):. PubMed ID: 30567361
[TBL] [Abstract][Full Text] [Related]
28. Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer.
Liu Y; Jiang H
Transl Androl Urol; 2020 Oct; 9(5):1937-1944. PubMed ID: 33209658
[TBL] [Abstract][Full Text] [Related]
29. De novo steroid biosynthesis in human prostate cell lines and biopsies.
Sakai M; Martinez-Arguelles DB; Aprikian AG; Magliocco AM; Papadopoulos V
Prostate; 2016 May; 76(6):575-87. PubMed ID: 26841972
[TBL] [Abstract][Full Text] [Related]
30. Hyaluronan-mediated motility receptor (RHAMM) immunohistochemical expression and androgen deprivation in normal peritumoral, hyperplasic and neoplastic prostate tissue.
Korkes F; de Castro MG; de Cassio Zequi S; Nardi L; Del Giglio A; de Lima Pompeo AC
BJU Int; 2014 May; 113(5):822-9. PubMed ID: 24053431
[TBL] [Abstract][Full Text] [Related]
31. Androgen deprivation therapy as backbone therapy in the management of prostate cancer.
Merseburger AS; Alcaraz A; von Klot CA
Onco Targets Ther; 2016; 9():7263-7274. PubMed ID: 27942220
[TBL] [Abstract][Full Text] [Related]
32. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; Van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Eur Urol; 2011 Apr; 59(4):572-83. PubMed ID: 21315502
[TBL] [Abstract][Full Text] [Related]
33. Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress.
Shiota M; Fujimoto N; Itsumi M; Takeuchi A; Inokuchi J; Tatsugami K; Yokomizo A; Kajioka S; Uchiumi T; Eto M
Ann Oncol; 2017 Mar; 28(3):569-575. PubMed ID: 27993795
[TBL] [Abstract][Full Text] [Related]
34. Cancer-driven IgG promotes the development of prostate cancer though the SOX2-CIgG pathway.
Qin C; Sheng Z; Huang X; Tang J; Liu Y; Xu T; Qiu X
Prostate; 2020 Sep; 80(13):1134-1144. PubMed ID: 32628304
[TBL] [Abstract][Full Text] [Related]
35. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
[TBL] [Abstract][Full Text] [Related]
36. [Correlation of FOXA1 with the malignancy and progression of prostate cancer].
Feng W; Zhang HB; Wang YM; Hu JL
Zhonghua Nan Ke Xue; 2015 May; 21(5):414-9. PubMed ID: 26117938
[TBL] [Abstract][Full Text] [Related]
37. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study.
Ji G; Song G; Huang C; He S; Zhou L
Medicine (Baltimore); 2017 Sep; 96(36):e7823. PubMed ID: 28885333
[TBL] [Abstract][Full Text] [Related]
38. [Correlation between the expression of Pim-1 and androgen-deprivation therapy for prostate cancer].
Wang J; Quan CY; Chang WL; Shang ZQ; Jiang N; Li B; Niu YJ
Zhonghua Nan Ke Xue; 2015 Sep; 21(9):775-81. PubMed ID: 26552208
[TBL] [Abstract][Full Text] [Related]
39. Periprostatic Fat Thickness on MRI is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Chinese Patients With Newly Diagnosed Prostate Cancer Treated With Androgen Deprivation Therapy.
Huang H; Chen S; Li W; Bai P; Wu X; Xing J
Clin Genitourin Cancer; 2019 Oct; 17(5):e1036-e1047. PubMed ID: 31281063
[TBL] [Abstract][Full Text] [Related]
40. Molecular and cellular mechanisms of castration resistant prostate cancer.
Huang Y; Jiang X; Liang X; Jiang G
Oncol Lett; 2018 May; 15(5):6063-6076. PubMed ID: 29616091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
